Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2013-03-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-013-2454-9PMID 23468242
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Myeloid growth factors.

  2013cited by this paper
• Costs Associated with Febrile Neutropenia in the US

  2012cited by this paper
• Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.

  2012cited by this paper
• 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

  2011cited by this paper
• Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study

  2011cited by this paper
• Risk of mortality in patients with cancer who experience febrile neutropenia

  2010cited by this paper
• Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer

  2010cited by this paper
• Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

  2009cited by this paper
• Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.

  2009cited by this paper
• NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

  2009cited by this paper
• Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study

  2008cited by this paper
• Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.

  2006cited by this paper
• Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

  2006cited by this paper
• Indications for propensity scores and review of their use in pharmacoepidemiology.

  2006cited by this paper
• First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

  2005cited by this paper
• Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

  2005cited by this paper
• Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.

  2005cited by this paper
• Risk models for predicting chemotherapy-induced neutropenia.

  2005cited by this paper
• New directions in the management of chemotherapy-induced neutropenia: Risk models, special populations, and quality of life.

  2003cited by this paper
• Epidemiology of febrile neutropenia.

  2003cited by this paper
• Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy

  2003cited by this paper
• Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.

  2002cited by this paper
• Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients.

  1998cited by this paper
• Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

  1998cited by this paper
• Splenomegaly in 2,505 patients in a large university medical center from 1913 to 1995. 1913 to 1962: 2,056 patients.

  1998cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• Infection, thyroid disease, and autoimmunity.

  1993cited by this paper
• Dose-response effect of adjuvant chemotherapy in breast cancer.

  1981cited by this paper
• PRIMARY SPLENIC NEUTROPENIA; A NEWLY RECOGNIZED SYNDROME, CLOSELY RELATED TO CONGENITAL HEMOLYTIC ICTERUS AND ESSENTIAL THROMBOCYTOPENIC PURPURA

  1942cited by this paper

• Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study

  2025cites this paper
• Granulocyte colony stimulating factor use and adherence to clinical practice guidelines among women with breast cancer living in Puerto Rico: a population-based study

  2022cites this paper
• Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study

  2022cites this paper
• Granulocyte Colony-Stimulating Factor Utilization and Prescribing Patterns in Cancer Patients: A Single Institution Experience of a Saudi Cancer Center

  2022cites this paper
• CMAR_A_313045 6207..6218

  2021cites this paper
• Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

  2021cites this paper
• A Poisson binomial-based statistical testing framework for comorbidity discovery across electronic health record datasets

  2021cites this paper
• Neutropenia in breast cancer patients receiving Paclitaxel as chemotherapy: a study in a tertiary care centre in Northeast India

  2021cites this paper
• Risk-Stratifying Treatment Strategies for Febrile Neutropenia-Tools, Tools Everywhere, and Not a Single One That Works?

  2021cites this paper
• A Poisson binomial based statistical testing framework for comprehensive comorbidity discovery across massive Electronic Health Record datasets

  2021cites this paper
• Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria

  2021cites this paper
• Association between sociodemographic factors and estrogen receptor-positive, progesterone receptor-positive breast cancer subtypes: A cross-sectional study

  2020cites this paper
• Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial

  2019cites this paper
• Incidence of Febrile Neutropenia in Advanced Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy in Korea and Its Impact on Prognosis

  2019cites this paper
• The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer

  2018cites this paper
• Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia

  2018cites this paper
• Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients

  2018cites this paper
• Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma

  2018cites this paper
• A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.

  2017cites this paper
• Neutropenic complications in Chinese patients with breast cancer in a real-world setting

  2017cites this paper
• Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice.

  2017cites this paper
• Racial and Ethnic Variability in the Prevalence and Incidence of Comorbidities Associated with Gastric Cancer in the United States

  2016cites this paper
• Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle

  2016cites this paper
• Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes.

  2015cites this paper
• Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.

  2015cites this paper
• Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use.

  2015cites this paper
• Risk Factors of Severe Neutropenia during Cancer Chemotherapy

  2014cites this paper
• Clinical Predictive Models for Chemotherapy-Induced Febrile Neutropenia in Breast Cancer Patients: A Validation Study

  2014cites this paper
• Avaliação do risco de complicações decorrentes de neutropenia febril em pacientes tratados no Instituto do Câncer do Estado de São Paulo

  2014cites this paper